| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000nam a2200000 i 4500 |
| 001 |
in00004675868 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
150328s2015 gw a ob 001 0 eng d |
| 005 |
20260214202000.6 |
| 020 |
|
|
|a 9783527673049
|q (electronic bk.)
|
| 020 |
|
|
|a 3527673040
|q (electronic bk.)
|
| 020 |
|
|
|a 9783527673025
|q (electronic bk.)
|
| 020 |
|
|
|a 3527673024
|q (electronic bk.)
|
| 020 |
|
|
|a 9783527673056
|q (electronic bk.)
|
| 020 |
|
|
|a 3527673059
|q (electronic bk.)
|
| 020 |
|
|
|a 9783527673032
|q (electronic bk.)
|
| 020 |
|
|
|a 3527673032
|q (electronic bk.)
|
| 020 |
|
|
|z 9783527335824
|q (print ;
|q alk. paper)
|
| 020 |
|
|
|z 352733582X
|q (print ;
|q alk. paper)
|
| 024 |
7 |
|
|a 10.1002/9783527673025
|2 doi
|
| 035 |
|
|
|a wil6007436
|
| 035 |
|
|
|a (NhCcYBP)wil6007436
|
| 040 |
|
|
|a NhCcYBP
|b eng
|e rda
|c NhCcYBP
|
| 050 |
|
4 |
|a RM301.25
|b .T44 2015eb
|
| 060 |
|
4 |
|a W1
|b ME9613h v.65 2015
|
| 060 |
|
4 |
|a QV 745
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 072 |
|
7 |
|a RS
|2 lcco
|
| 082 |
0 |
4 |
|a 615.19
|2 23
|
| 245 |
0 |
0 |
|a Thermodynamics and kinetics of drug binding /
|c edited by György M. Keserü and David C. Swinney.
|
| 264 |
|
1 |
|a Weinheim, Germany :
|b Wiley-VCH Verlag GmbH & Co. KGaA,
|c [2015]
|
| 300 |
|
|
|a 1 online resource (xxiii, 334 pages) :
|b illustrations (some color)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Methods and principles in medicinal chemistry ;
|v volume 65
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 520 |
|
|
|a "This practical reference for medicinal and pharmaceutical chemists combines the theoretical background with modern methods as well as applications from recent lead finding and optimization projects. Divided into two parts on the thermodynamics and kinetics of drug-receptor interaction, the text provides the conceptual and methodological basis for characterizing binding mechanisms for drugs and other bioactive molecules. It covers all currently used methods, from experimental approaches, such as ITC or SPR, right up to the latest computational methods. Case studies of real-life lead or drug development projects are also included so readers can apply the methods learned to their own projects. Finally, the benefits of a thorough binding mode analysis for any drug development project are summarized in an outlook chapter written by the editors."--
|c Publisher's info.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Keserü 4.1 Introduction 63 4.2 TheThermodynamics of Medicinal Chemistry Optimizations 66 4.3 Selection of Suitable Starting Points 70 4.4 Thermodynamics Based Optimization Strategies 73 References 78 5 From Molecular Understanding to Structure-Thermodynamic Relationships, the Case of Acetylcholine Binding Proteins 81 ; Antoni R. Blaazer and Iwan J. P. de Esch 5.1 Introduction 81 5.1.1 Natural nAChR Ligands 82 5.1.2 nAChR Ligands as Therapeutic Agents 83 5.2 Acetylcholine Binding Proteins (AChBPs) 85 5.3 Thermodynamics of Small Molecule Binding at AChBPs 89 5.4 Concluding Remarks and Outlook 98 References 99 6 Thermodynamics in Lead Optimization 107 ; Geoffrey A.
|
| 505 |
0 |
|
|a Holdgate, Andrew Scott, and Gareth Davies 6.1 Introduction to Lead Optimization in Drug Discovery 107 6.2 Measurement ofThermodynamic Parameters in Lead Optimization 111 6.3 Advantages during Lead Optimization for Thermodynamic Measurements 117 6.4 Exploitation of Measured Thermodynamics in Lead Optimization 118 6.5 Lead Optimization beyond Affinity 120 6.6 Exemplary Case Studies 123 6.7 Potential Complicating Factors in Exploiting Thermodynamics in Lead Optimization 126 6.8 Summary 132 References 133 7 Thermodynamic Profiling of Carbonic Anhydrase Inhibitors 137 ; Lyn H. Jones 7.1 Introduction 137 7.2 Thermodynamic Profiles of Fragment Inhibitors 139 7.3 Thermodynamics of Fragment Growing 146 7.4 Conclusions 147 Acknowledgments 148 References 149 Section II: Kinetics 155 8 Drug-Target Residence Time 157 ; Robert A.
|
| 505 |
0 |
|
|a Copeland 8.1 Introduction 157 8.2 Open and Closed Systems in Biology 157 8.3 Mechanisms of Drug-Target Interactions 159 8.4 Impact of Residence Time on Cellular Activity 161 8.5 Impact on Efficacy and Duration In vivo 163 8.6 Limitations of Drug-Target Residence Time 166 8.7 Summary 167 References 167 9 Experimental Methods to Determine Binding Kinetics 169 ; Georges Vauquelin, Walter Huber, and David C. Swinney 9.1 Introduction 169 9.2 Definitions 170 9.3 Experimental Strategy 171 9.4 Experimental Methodologies 172 9.5 Specific Issues 183 9.6 Conclusion 185 Acknowledgment 185 References 185 10 Challenges in the Medicinal Chemical Optimization of Binding Kinetics 191 ; Michael J.Waring, Andrew G.
|
| 505 |
0 |
|
|a Leach, and Duncan C.Miller 10.1 Introduction 191 10.2 Challenges 192 10.3 Optimization in Practice 199 10.4 Summary and Conclusions 208 References 209 11 Computational Approaches for Studying Drug Binding Kinetics 211 ; Julia Romanowska, Daria B. Kokh, Jonathan C.
|
| 505 |
0 |
|
|a Fuller, and Rebecca C.Wade 11.1 Introduction 211 11.2 Theoretical Background 211 11.3 Model Types and Force Fields 218 11.4 Application Examples 222 11.5 Summary and Future Directions 228 Acknowledgments 228 References 229 12 The Use of Structural Information to Understand Binding Kinetics 237 ; Felix Schiele, Pelin Ayaz, and Anke Müller-Fahrnow 12.1 Introduction 237 12.2 Binding Kinetics 238 12.3 Methods to Obtain Structural Information to Understand Binding Kinetics 241 12.4 Literature on Structure Kinetic Relationships 242 12.5 Current Thinking on the Structural Factors That Influence Binding Kinetics 251 12.6 Concluding Remarks 252 References 253 13 Importance of Drug-Target Residence Time at G Protein-Coupled Receptors - a Case for the Adenosine Receptors 257 ; Dong Guo, Adriaan P. IJzerman, and Laura H.
|
| 505 |
0 |
|
|a Heitman 13.1 Introduction 257 13.2 The Adenosine Receptors 257 13.3 Mathematical Definitions of Drug-Target Residence Time 258 13.4 Current Kinetic Radioligand Assays 260 13.5 Dual-Point Competition Association Assay: a Fast and High-Throughput Kinetic Screening Method 261 13.6 Drug-Target Residence Time: an Often Overlooked Key Aspect for a Drug's Mechanism of Action 267 13.7 Conclusions 270 Acknowledgments 271 References 271 14 Case Study: Angiotensin Receptor Blockers (ARBs) 273 ; Georges Vauquelin 14.1 Introduction 273 14.2 Insurmountable Antagonism 275 14.3 From Partial Insurmountability to an Induced Fit-Binding Mechanism 280 14.4 Sartan Rebinding Contributes to Long-Lasting AT1-Receptor Blockade 283 14.5 Summary and Final Considerations 287 References 288 15 The Kinetics and Thermodynamics of Staphylococcus aureus FabI Inhibition
|
| 505 |
0 |
|
|a 295 ; Andrew Chang, Kanishk Kapilashrami, Eleanor K. H. Allen, and Peter J. Tonge 15.1 Introduction 295 15.2 Fatty Acid Biosynthesis as a Novel Antibacterial Target 296 15.3 Inhibition of saFabI 297 15.4 Computer-Aided Enzyme Kinetics to Characterize saFabI Inhibition 298 15.5 Orthogonal Methods to Measure Drug-Target Residence Time 298 15.6 Mechanism-Dependent Slow-Binding Kinetics 303 15.7 Mechanistic Basis for Binary Complex Selectivity 303 15.8 Rational Design of Long Residence Time Inhibition 304 15.9 Summary 306 References 307 Section III: Perspective 313 16 Thermodynamics and Binding Kinetics in Drug Discovery 315 ; György M. Keserü and David C.
|
| 505 |
0 |
|
|a Swinney 16.1 Introduction 315 16.2 Reaction Coordinate 316 16.3 Competing Rates 317 16.4 Thermodynamic Controlled Process - Competing Rates under Equilibrium Conditions 317 16.5 Kinetics Controlled Processes - Competing Rates under Non-equilibrium Conditions 318
|
| 546 |
|
|
|a English.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
0 |
|a Binding sites (Biochemistry)
|x Thermodynamics.
|
| 650 |
|
0 |
|a Pharmacokinetics.
|
| 650 |
|
0 |
|a Drug receptors.
|
| 650 |
|
0 |
|a Ligands.
|
| 650 |
|
0 |
|a Thermodynamics.
|
| 650 |
1 |
2 |
|a Drug Discovery
|
| 650 |
1 |
2 |
|a Receptors, Drug
|
| 650 |
2 |
2 |
|a Ligands
|
| 650 |
2 |
2 |
|a Thermodynamics
|
| 650 |
2 |
2 |
|a Pharmacokinetics
|
| 700 |
1 |
|
|a Keserü, G. M.,
|e editor.
|
| 700 |
1 |
|
|a Swinney, David Carl,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Thermodynamics and kinetics of drug binding
|z 9783527335824
|
| 830 |
|
0 |
|a Methods and principles in medicinal chemistry ;
|v v. 65.
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://onlinelibrary.wiley.com/book/10.1002/9783527673025
|z Connect to the full text of this electronic book
|t 0
|
| 955 |
|
|
|a Wiley EBA record
|
| 975 |
|
|
|p Wiley UBCM Full Collection 2026
|
| 999 |
f |
f |
|s 735f9d99-a299-40c4-9290-77e74a3d5738
|i 2e79fc7d-8593-44b3-8886-f6163b2ee1ac
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s evans_pda
|d Available Online
|t 0
|e RM301.25 .T44 2015eb
|h Library of Congress classification
|
| 998 |
f |
f |
|a RM301.25 .T44 2015eb
|t 0
|l Available Online
|